Systemic inflammation is prevalent in obesity, and it is one of the key determinants of failure of anti-TNF agents, with each unit increase in BMI associated with 6.5% of failing therapy [65]. This evidence concerns the gene TNF and obesity due to melanocortin 4 receptor deficiency.